Exploration and evaluation of novel pharmacological approaches for attenuation of nicotine dependence induced withdrawal syndrome in mice
Loading...
Date
item.page.authors
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
newline The present study investigated the effect of SU-6656; ammonium pyrrolidine dithiocarbamate (APD); RS 102895; Ro 32-0432 hydrochloride; and FTI-276 trifluoroacetate on propagation of nicotine dependence and resultant withdrawal signs in vivo. The experimental protocol consisted of administration of nicotine, (2.5 mg/kg, subcutaneously), four times daily for 7 days. In order to precipitate nicotine withdrawal, mice were given one injection of mecamylamine (3 mg/kg, intraperitoneally, i.p), 1 h after the last nicotine injection on the test day (day 8). Behavioral observations were made for a period of 30 min immediately after mecamylamine treatment. Withdrawal syndrome was quantitated in terms of a composite withdrawal severity score, Jumping Frequency, Hyperalgesia and withdrawal syndrome related anxiety was assessed by elevated plus maze test results. SU-6656; ammonium pyrrolidine dithiocarbamate (APD); RS 102895; Ro 32-0432 hydrochloride; and FTI-276 trifluoroacetate dose dependently attenuated mecamylamine induced experimental nicotine withdrawal syndrome in vivo models. Therefore, it may be concluded that the inhibition of Src-kinase; nuclear factor kappa B; chemokine CCR-2 receptor; G-protein couple receptor kinase-5 and Farnesyltransferase-I to which the compounds have shown affinity, will in all probability be involved in attenuation of the development of Nicotine dependence as observed in the mecamylamine-induced precipitation of withdrawal symptoms in Nicotine dependent mice.
newline Keywords: Nicotine dependence; withdrawal syndrome; nicotine; mecamylamine; Src-kinase; Nuclear factor kappa B; Chemokine CCR-2 receptor; G-protein couple receptor kinase-5 and Farnesyltransferase-I.